Log in

NYSE:ARAAmerican Renal Associates Stock Price, Forecast & News

-0.02 (-0.30 %)
(As of 07/9/2020 04:00 PM ET)
Today's Range
Now: $6.61
50-Day Range
MA: $6.30
52-Week Range
Now: $6.61
Volume195,500 shs
Average Volume130,737 shs
Market Capitalization$223.02 million
P/E Ratio25.42
Dividend YieldN/A
American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of June 30, 2018, it owned and operated 233 dialysis clinics in partnership with 400 nephrologist partners treating approximately 16,000 patients in 26 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.
Read More
American Renal Associates logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified



Sales & Book Value

Annual Sales$822.52 million
Cash Flow$1.69 per share
Book Value$2.59 per share


Net Income$-13,790,000.00


Market Cap$223.02 million
Next Earnings Date8/10/2020 (Estimated)

Receive ARA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARA and its competitors with MarketBeat's FREE daily newsletter.

American Renal Associates (NYSE:ARA) Frequently Asked Questions

How has American Renal Associates' stock been impacted by COVID-19 (Coronavirus)?

American Renal Associates' stock was trading at $7.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARA stock has decreased by 7.4% and is now trading at $6.61. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of American Renal Associates?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for American Renal Associates in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for American Renal Associates.

When is American Renal Associates' next earnings date?

American Renal Associates is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for American Renal Associates.

How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings Inc (NYSE:ARA) released its earnings results on Monday, May, 11th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.07. The company had revenue of $193.18 million for the quarter, compared to analysts' expectations of $201.73 million. American Renal Associates had a negative net margin of 2.14% and a positive return on equity of 16.46%. View American Renal Associates' earnings history.

What price target have analysts set for ARA?

3 Wall Street analysts have issued 1 year price objectives for American Renal Associates' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate American Renal Associates' share price to reach $8.67 in the next year. This suggests a possible upside of 31.1% from the stock's current price. View analysts' price targets for American Renal Associates.

Has American Renal Associates been receiving favorable news coverage?

News coverage about ARA stock has been trending negative on Friday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. American Renal Associates earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about American Renal Associates.

Who are some of American Renal Associates' key competitors?

What other stocks do shareholders of American Renal Associates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include Akorn (AKRX), Exelixis (EXEL), Amicus Therapeutics (FOLD), KemPharm (KMPH), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), AbbVie (ABBV), Collegium Pharmaceutical (COLL), Catalyst Pharmaceuticals (CPRX) and Fate Therapeutics (FATE).

Who are American Renal Associates' key executives?

American Renal Associates' management team includes the following people:
  • Mr. Joseph A. Carlucci, Co-Founder, CEO & Chairman (Age 65)
  • Mr. Syed T. Kamal, Founder, Pres & Director (Age 66)
  • Mr. Mark C. Herbers, Interim CFO & Interim Chief Accounting Officer (Age 64)
  • Dr. Don E. Williamson, Exec. VP & COO (Age 56)
  • Mr. Richard Pacheco CFE, AVA, MBA, VP of Admin.

When did American Renal Associates IPO?

(ARA) raised $161 million in an initial public offering on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

What is American Renal Associates' stock symbol?

American Renal Associates trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARA."

Who are American Renal Associates' major shareholders?

American Renal Associates' stock is owned by a variety of retail and institutional investors. Top institutional investors include Tsfg LLC (0.03%). View institutional ownership trends for American Renal Associates.

Which institutional investors are buying American Renal Associates stock?

ARA stock was bought by a variety of institutional investors in the last quarter, including Tsfg LLC. View insider buying and selling activity for American Renal Associates.

How do I buy shares of American Renal Associates?

Shares of ARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is American Renal Associates' stock price today?

One share of ARA stock can currently be purchased for approximately $6.61.

How big of a company is American Renal Associates?

American Renal Associates has a market capitalization of $223.02 million and generates $822.52 million in revenue each year. The company earns $-13,790,000.00 in net income (profit) each year or $0.26 on an earnings per share basis. American Renal Associates employs 4,977 workers across the globe.

What is American Renal Associates' official website?

The official website for American Renal Associates is www.americanrenal.com.

How can I contact American Renal Associates?

American Renal Associates' mailing address is 500 CUMMINGS CENTER SUITE 6550, BEVERLY MA, 01915. The company can be reached via phone at 978-922-3080 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.